There are only two weeks to go until the 31 October deadline, don’t miss it – get your entry in now!
Highlighting this important area of work within the pharmaceutical industry, the new Medical & Scientific Excellence Awards are designed to recognise the outstanding achievements of medical and scientific professionals.
A pivotal Phase III trial investigating a combination of MSD’s anti-PD-1 therapy Keytruda and Pfizer’s tyrosine kinase inhibitor Inlyta has shown a significant benefit on both overall (OS) and progression-free survival (PFS) in patients with kidney cancer.
Shire’s prucalopride has taken a giant leap towards approval after winning the support of an FDA advisory committee for chronic idiopathic constipation.
ViiV Healthcare has submitted a New Drug Application to the US Food and Drug Administration seeking permission to market a single-tablet, two-drug regimen of dolutegravir and lamivudine for the treatment of HIV.
As it stands Eli Lilly’s Verzenios will not be routinely funded on the NHS for breast cancer, as cost-regulators have now issued draft guidelines rejecting the drug.
Health secretary Matt Hancock has unveiled his vision for technology in healthcare, which, he claims, will lay the foundation for a new generation of digital services able to meet the needs of clinicians, patients and managers.
The NHS now has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available to eligible skin cancer patients, after cost regulators published guidance backing funds for the treatment.
Allergan is gearing up to file its oral CGRP receptor ubrogepant in the US for the treatment of migraine, following the success and completion of two safety studies.
Novartis has signed a deal to acquire US biopharma Endocyte, securing itself access to novel radiopharmaceutical programmes “with significant sales potential”.
London’s “complex and cluttered” health and care system is holding back plans to improve the health of its population, finds a new independent report from The King’s Fund.
AstraZeneca and MSD’s PARP inhibitor Lynparza has been granted orphan drug designation in the US for the treatment of pancreatic cancer.
Samsung Bioepis has announced the European launch of Humira biosimilar Imraldi, as NHS chiefs tell Trusts to ensure they are ready to realise the potential savings from using cheaper versions of the world’s biggest selling drug.
Dr Falk Pharma has launched Jorveza – the first globally licensed drug approved for eosinophilic oesophagitis – across the UK.
US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad.
Sanofi and Regeneron have unveiled top-line data showing that two late-stage studies of Dupixent in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps met all their primary and secondary endpoints.
